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ABSTRACT
Respiratory tract infections are a frequent cause of medical consultations. Although the majority of such
infections are viral in aetiology, they account for three-quarters of all antibiotic consumption, since
bacterial infections of the upper and lower respiratory tract, notably bronchitis, sinusitis and pneumonia,
are the most frequent complications resulting from virus infections, especially inﬂuenza in adults and
children. The resulting widespread use of antibiotics is a primary factor that drives the emergence of
antibiotic resistance at both the local and regional levels. Recent surveys suggest that the proportion of
patients with inﬂuenza-like illness who receive antibiotics is at least double the actual incidence of the
infections for which the treatment is intended. Inappropriate prescribing needs to be tackled by
encouraging more rigorous diagnosis, prevention and treatment of viral infections, speciﬁcally inﬂuenza.
Although accurate diagnosis of inﬂuenza is challenging, rapid tests to identify the causative pathogen,
e.g., RT-PCR tests for inﬂuenza viruses, are becoming more reliable and affordable. The use of antiviral
drugs, particularly neuraminidase inhibitors, is a speciﬁc and effective way of preventing and treating
inﬂuenza, and has been shown to reduce the incidence of complications and associated antibiotic use. In
contrast to bacterial resistance to antibiotics, viral resistance to neuraminidase inhibitors is low, and their
high speciﬁcity means that they cannot exert selection pressure on any other species. The widespread
adoption of these principles may have a signiﬁcant effect on antimicrobial use and resistance.
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INTRODUCTION
The number of antibiotic-resistant microorgan-
isms has increased in the past decade as a result
of increased use of antibiotics in children and the
excessive use of antibiotics in adults. The majority
of antibiotics prescribed to adults in ambulatory
practice are for acute respiratory tract infections
(RTIs), particularly acute sinusitis, acute pharyn-
gitis, acute bronchitis and non-speciﬁc upper
respiratory tract infections (URTIs), including
the common cold [1]. Inﬂuenza is associated with
excess rates of hospitalisation and mortality dur-
ing disease outbreaks, particularly in the elderly
and in children [2,3]. This burden stems largely
from secondary complications arising from the
primary viral infection, the most common of
which are bacterial infections of the respiratory
tract, notably pneumonia and bronchitis. In
children, otitis media is the most common
complication of infection. The level of antibiotic
prescribing in patients with inﬂuenza still appears
to be seriously out of proportion to the number of
bacterial infections that actually occur. This
review considers the challenge of appropriate
antimicrobial prescribing in patients with inﬂu-
enza infection.
SECONDARY BACTERIAL
INFECTIONS IN INFLUENZA
The most commonly encountered bacterial infec-
tions following primary inﬂuenza infection in
adults principally affect the respiratory system.
Susceptibility to secondary infection of the lungs
and bronchi by bacteria, e.g., Streptococcus pneu-
moniae and Haemophilus inﬂuenzae, seems to result
from increased binding of bacteria to the basal
membrane of the respiratory epithelium [4]. This
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may be the result of direct viral damage [5] or viral
activation of receptors on the epithelial cell that
can directly bind bacteria, e.g., the receptor for
platelet-activating factor [6]. Inﬂuenza virus has
also been shown to increase susceptibility by
reducing neutrophil function [7] and by increasing
the production of cytokines such as interleukin-10
[8]. A pneumococcal enzyme, neuraminidase,
improves colonisation by cleaving N-acetylneur-
aminic acid from mucin, thereby decreasing the
viscosity of the mucus. Neuraminidase also
cleaves glycolipids, glycoproteins and oligosac-
charides, and is thus thought to bring about
exposure of N-acetylglycosamine receptors on
the host epithelial cells [9]. The neuraminidase
activity of viruses such as inﬂuenza and parain-
ﬂuenza viruses might thereby contribute to the
increased adherence of pneumococci that can be
observed during viral infections [10].
Estimates of the incidence of inﬂuenza-associ-
ated RTIs vary considerably, depending on
factors such as country, season, age group and
viral strain. A comparison of infection rates in
over 140 000 cases of inﬂuenza and inﬂuenza-like
illness (ILI) with matched controls in adults and
children in the UK General Practice Research
Database revealed an excess of inﬂuenza-associ-
ated bacterial infections [11]. The great majority of
these were URTIs and acute bronchitis (incidence
of 5.51% and 1.48%, respectively), followed by
otitis media (1.05%) and pneumonia (0.38%).
A pooled analysis of >2400 patients infected with
inﬂuenza virus who took part in ten clinical
studies revealed higher incidence values of 8.2%
for bronchitis and 1.8% for pneumonia [12]. In
contrast, an incidence of 19% was estimated for
acute bronchitis during the 1989 UK inﬂuenza
epidemic [13], and another general practice sur-
vey of patients with inﬂuenza or ILI during the
Italian winter epidemic of 1998–1999 revealed that
15% had bronchitis, and a further 15% had
URTIs, while sinusitis and pneumonia were
reported in 3.2% and 1.4% of patients, respec-
tively [14].
Although much less common than bronchitis,
bacterial pneumonia, often occurring in tandem
with viral pneumonia, has more serious conse-
quences. The infecting species is typically Staphy-
lococcus aureus, but Strep. pneumoniae and
H. inﬂuenzae are also commonly isolated [15].
Patients with bacterial pneumonia are very likely
to need hospital treatment, and the mortality rate
is high, particularly in patients who are elderly or
who have cardiovascular or respiratory illness [3],
in whom pneumonia is much more frequent than
in other adults. Of 178 elderly individuals residing
in a group of Canadian nursing homes who were
infected with inﬂuenza during the 1999–2000
outbreak, 37 (21%) had bacterial pneumonia [16].
Secondary bacterial respiratory tract infections
are a frequent complication in children as well as
adults, but the most common bacterial infection
associated with childhood inﬂuenza is otitis
media. In a clinical study of children aged
1–12 years, tympanometrically conﬁrmed otitis
media was found in 37 (18.5%) of 200 children
in the placebo group [17], which is the same
incidence as reported in inﬂuenza-positive chil-
dren up to 14 years of age during two consecutive
seasons [18]. In a study of vaccine efﬁcacy, 20
(21%) of 95 children aged 1–5 years in the placebo
group had inﬂuenza-associated otitis media [19].
Secondary infections in children with inﬂuenza
increase the demand for antibiotics, accounting,
on aggregate, for up to 30% of all excess use
during the inﬂuenza season [20]. During the
1918–1919 pandemic, a second wave of infection
spread globally between September and Novem-
ber 1918, and had a high fatality rate [21,22].
Many deaths were the result of secondary bacte-
rial pneumonia [23].
THE NEED TO REDUCE
INAPPROPRIATE ANTIBIOTIC USE
Since their discovery during the 20th century,
antimicrobial agents have substantially reduced
the threat posed by infectious diseases. These
gains are now seriously jeopardised by the emer-
gence and spread of microbes that are resistant to
effective ﬁrst-choice drugs. Reducing resistance
rates by limiting and optimising therapy of RTIs
is an important strategy.
Strep. pneumoniae is the most common bacterial
pathogen in RTIs, being implicated each year in
500 000 cases of pneumonia and >7 million cases
of otitis media in the USA alone [24]. Worldwide,
pneumococcal disease is one of the leading causes
of mortality, particularly among children, the
elderly and those with co-morbid illnesses.
Increasing resistance to penicillins and macro-
lides, reaching 30–40% among isolates in many
areas, is therefore of considerable concern [25].
Macrolide resistance in Strep. pneumoniae now
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exceeds penicillin resistance in some regions,
and continues to increase. Pneumococcal
ﬂuoroquinolone resistance remains rare, but will
inevitably increase as these agents are employed
more widely to treat RTIs.
The selection of antibiotic resistance is inevita-
ble. The overall volume of antibiotic prescribing is
the primary factor driving resistance at both the
local and regional levels, although other inﬂu-
ences, notably clonal spread, complicate epidemi-
ological analysis. It is therefore necessary to
educate prescribers concerning the need to avoid
antibiotic therapy when there is no clinical indi-
cation. The problems of resistance to penicillins
and macrolides, arising from antibiotic misuse
and overuse, are well-established [26–31], and
advice on how to counter these trends is readily
available in treatment guidelines [32–35].
Whether such advice has brought about changes
in prescribing practice is a moot point. For
example, a large general practice survey during
the Italian winter epidemic of 1998–1999 found
complications in c. 35% of patients with inﬂuenza
or ILI. However, c. 36% of the patients received
antibiotics, suggesting that the rate of prescribing
was appropriate [14]. A survey in the UK of >100
primary-care practices showed that antibiotic use
for respiratory infections fell by 45% between
1994 and 2000, but that this was more the result of
a reduction in consultations than a reduction in
inappropriate prescription [36]. The National
Ambulatory Medical Care Surveys (NAMCS) in
the USA showed a reduction in prescribing rates
for common respiratory infections in children and
adolescents during 1990–2000 [37], but the picture
was less clear in adults, with decreases in the use
of penicillins, cephalosporins and erythromycin
between 1992 and 2000, but large increases in the
use of other macrolides and quinolones [38].
During the same decade, antibiotic use in France,
which is the biggest consumer of antibiotics per
capita in Europe, increased slightly [39]. In
Canada, although the prevalence of penicillin
non-susceptibility stabilised in association with a
reduction in b-lactam use, an increase in amoxy-
cillin non-susceptibility was observed, beginning
in 2001. This was caused by the proliferation of
the 19F-14 clone (a vaccine serotype). Erythro-
mycin resistance was correlated strongly with use
of azithromycin and clarithromycin, while an
inverse relationship existed for erythromycin.
Non-susceptibility to tetracyclines continued to
increase in Canada during the surveillance peri-
od, despite decreasing use of these agents. This
ﬁnding has been noted in previous surveillance
studies, and may be best explained by co-selection
of the tetracycline resistance gene tet(M) with the
macrolide resistance gene erm(B). Fluoroquino-
lone resistance rates have stabilised in Canada
since 1998, despite increasing use of these agents.
A possible explanation is the increase in the use of
ﬂuoroquinolones that have greater activity for the
treatment of RTIs caused by pneumococci (46th
Interscience Conference on Antimicrobial Agents
and Chemotherapy, abstract C2-433).
Antibiotic misuse
The use of antibiotics to treat a viral infection such
as inﬂuenza is doubly misguided, since antibiot-
ics have no effect on an infection of solely viral
origin, and the use of antibiotics will exert
selection pressure on bacteria carried by the
treated individual, adding to the risk of generat-
ing resistance. A survey of US primary-care
patients who received an antibiotic for a respira-
tory tract infection reported no overall improve-
ment in several patient-reported outcomes or
follow-up clinic visits [40]. Similar ﬁndings were
reported for patients with ILI during the 1999–
2000 inﬂuenza epidemic in France [41]; those who
received antibiotics did not beneﬁt in terms of
symptom relief, absence from work or avoidance
of follow-up visits.
The evidence of continuing misuse of antibiot-
ics in an attempt to treat viral respiratory infec-
tions such as inﬂuenza is of particular concern.
An analysis of NAMCS data from 1992 revealed
that acute rhinosinusitis and acute bronchitis,
which are nearly always caused by viruses,
accounted for 21% of all antibiotic prescriptions
for adults [42]. Despite a call in 1997 to address
inappropriate prescribing [43], a survey of
>15 000 adults making outpatient visits in North
Carolina, USA in 2000–2001 for inﬂuenza or acute
URTIs, bronchitis, pharyngitis or nasopharyngitis
revealed that 63% received oral antibiotics [44].
A nationwide US survey published a year later
showed that 38% of >6.5 million visits (primary
practice, outpatient and emergency room) by
children and adults aged 5–49 years with a sole
diagnosis of inﬂuenza were associated with an
antibiotic prescription [45]. The picture in other
countries is consistent with that in North
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America. The majority of antibiotics prescribed in
France during 1992–2000 were for URTIs, i.e.,
conditions very likely to be viral in origin [39].
A survey of a large general practitioner database
in Italy by Mazzaglia et al. [46] reported a high
rate of antibiotic prescribing to adolescents, adults
and elderly patients for acute respiratory infec-
tions (63%) and, more disturbingly, for inﬂuenza,
croup and common cold (44%). Even higher rates
were revealed by a survey of hospital emergency
departments in Spain [47], in which an expert
panel judged that >70% of prescriptions for
inﬂuenza, croup or colds were inappropriate.
Studies in children provide a similarly
discouraging picture. Although 18.5% of 392
children with conﬁrmed inﬂuenza in Greece
during the inﬂuenza season were found to have
otitis media, antibiotics were prescribed to 39.5%
of these children, most commonly to those aged
<2 years [18]. Similar levels of prescribing were
revealed by a representative survey (using 1992
NAMCS data) of US children, which found that
antibiotics were given to 44% of children and
adolescents aged <18 years who had colds, and
to 46% of those with URTIs [48]. During the 2002
epidemic in France, a survey of children aged
<3 years admitted to emergency departments
with ILI considered that >80% of the prescrip-
tions for antibiotics were inappropriate [49].
Diagnostic challenges
One factor leading to the inappropriate prescrib-
ing of antibiotics for inﬂuenza is the difﬁculty of
making a reliable diagnosis of the disease.
Distinguishing between viral and bacterial respi-
ratory infections on the basis of clinical features
alone is very difﬁcult. Scoring systems for sore
throat symptoms have been tested and validated
[50], but have not proved easy to use in practice
[51]; thus, avoiding needless use of an antibiotic
requires tests to identify the infecting pathogen.
For example, treatment of sore throats with pen-
icillin V is only effective in those individuals who
test positive for group A streptococci (GAS) [52],
so rapid tests for detection of GAS that are highly
sensitive and speciﬁc can improve the efﬁciency of
prescribing. Increased levels of C-reactive protein
can also indicate the presence of bacterial infec-
tion, and use of rapid tests for C-reactive protein
has been shown to reduce antibiotic prescribing in
patients with sinusitis [53].
Eliminating the possibility of bacterial infection
still leaves the challenge of identifying whether
inﬂuenza virus is the cause of an illness, since
patients infected with other respiratory viruses,
e.g., respiratory syncytial virus, present with
clinical features very similar to those of inﬂuenza,
including complications such as secondary infec-
tions [18]. The sensitivity and predictive value of
a given clinical deﬁnition of inﬂuenza vary
according to how widely inﬂuenza and other
respiratory pathogens are circulating in the com-
munity [54], and the clinical features of ILI are
usually not sufﬁciently speciﬁc to conﬁrm or
exclude inﬂuenza [55]. A case-deﬁnition includ-
ing cough and fever was 78% sensitive and 55%
speciﬁc (and had 87% predictive value) for
laboratory-conﬁrmed inﬂuenza during the Cana-
dian inﬂuenza season of 1998–1999 [56]; similarly,
the combination of cough and fever had a positive
predictive value of 79% in a retrospective analysis
of subjects in international clinical trials [57]. The
inaccuracy inherent in the clinical diagnosis of
inﬂuenza underlines the importance of laboratory
tests to conﬁrm the identity of the pathogen.
Rapid tests based on immunoassays or neuramin-
idase activity can detect inﬂuenza A and B
viruses, but the sensitivity and, to a lesser extent,
speciﬁcity of immunoassays is inferior to that of
viral culture or RT-PCR assays [58]. RT-PCR is
more sensitive [59], and may be adopted routinely
as it becomes more affordable. Serology and viral
culture have greater value for retrospective con-
ﬁrmation of infection, e.g., in surveillance studies.
ANTIVIRAL THERAPY
The neuraminidase inhibitors (NIs) zanamivir
and oseltamivir are antiviral agents that were
developed during the 1990s speciﬁcally for the
treatment and prophylaxis of inﬂuenza. These
agents have a therapeutic advantage over older
antiviral drugs, e.g., rimantadine and amanta-
dine, in that they are active against inﬂuenza B as
well as inﬂuenza A viruses, they are tolerated
much more readily, and the emergence of resis-
tance occurs infrequently. Clinical trials have
established that NIs are effective in reducing the
severity and duration of inﬂuenza in adults and
adolescents [60–63] as well as in children [17,64].
Several large controlled studies of the use of NIs
for disease prevention have demonstrated that
zanamivir and oseltamivir are effective in
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preventing the clinical symptoms of inﬂuenza in
healthy adults when the drugs are used either as
prophylaxis for close contacts, e.g., household
members after exposure, or as seasonal prophy-
laxis in the community. These studies revealed
that the incidence of both inﬂuenza A and inﬂu-
enza B infections was reduced by 70–90% when
NIs were used for prophylaxis either before or
after exposure to the virus [65].
An additional beneﬁt of treating inﬂuenza with
NIs is the reduction in the need for antibiotics to
treat secondary infections. An early randomised
controlled study in southern hemisphere coun-
tries revealed that zanamivir treatment reduced
the relative risk of antibiotic use by 13% as
compared with a placebo, and that the risk
reduction was 65% in a subgroup of high-risk
patients [66]. These ﬁndings were conﬁrmed in a
later pooled analysis of seven clinical studies of
the use of zanamivir for the treatment of adults
and adolescents with inﬂuenza, which showed a
relative risk reduction of 26% as compared with a
placebo [61]. A similar degree of reduction in
antibiotic use (26.7%) was seen in a pooled
analysis of ten treatment studies of the use of
oseltamivir in adults, adolescents and the elderly
[12]; in addition, only 4.6% of inﬂuenza patients
treated in this study reported bronchitis, lower
respiratory tract infections or pneumonia, as
compared with 10.3% of those receiving a placebo
[12]. These beneﬁts have also been shown in
clinical practice. A retrospective cohort survey,
using claims data from a US health insurance
database [67], investigated antibiotic use in indi-
viduals diagnosed with ILI, and showed a relative
risk reduction of 11% for the oseltamivir group as
compared with the no-antiviral group; the inci-
dences of pneumonia in the two groups were
1.3% and 2.6%, respectively, representing a risk
reduction following treatment of 28% (Table 1)
[67].
As described above, elderly patients and adults
with inﬂuenza and a co-existing illness, e.g., lung
or heart disease, have more frequent infections
and are heavier users of antibiotics. Treatment
with NIs has been shown to be particularly
beneﬁcial in this group. For example, in a pooled
analysis of high-risk adults and children, mostly
with chronic respiratory conditions, who took
part in clinical trials of zanamivir [68], the
incidences of complications requiring antibiotic
treatment in the inﬂuenza-positive patients in this
analysis were 13% for the treated group and 24%
for those receiving a placebo, representing a
reduction in relative risk of 43%. Similar results
were seen in a study of nursing home residents
taking antiviral agents as treatment or prophy-
laxis for inﬂuenza [16]. Despite the small number
of individuals included in the analysis, residents
who received oseltamivir within 48 h of the onset
of symptoms, or who were taking oseltamivir as
prophylaxis, had signiﬁcantly lower rates of
antibiotic use and fewer complications and deaths
than individuals in the other groups. Children
with inﬂuenza accrue similar beneﬁts from
NI treatment to adults. Oseltamivir reduced the
incidence of complications requiring antibiotics in
children by 40% as compared with placebo, and
reduced the relative risk of otitis media by 44%
[17].
The level of success achieved in shortening the
duration of inﬂuenza episodes with NI treatment
depends very closely on how early treatment can
be initiated, reﬂecting the importance of inhibit-
ing viral replication as soon as possible after
infection. This was ﬁrst reported in a phase III
clinical study of zanamivir, which, whether
administered by inhalation or by a combination
of the inhaled and intranasal routes, resolved
major inﬂuenza symptoms in 4 days (median)
when given within 30 h of the onset of symptoms,
as compared with a median of 5 days when given
later [60]. Minimising the delay before the initi-
ation of treatment also improves treatment effec-
tiveness for oseltamivir; this was ﬁrst shown in
the study by Nicholson et al. [62] and then
subsequently conﬁrmed in the IMPACT study
[69]. The latter study speciﬁcally analysed the
effect of treatment initiation time (ranging from
0–6 h after symptom onset to 36–48 h) on
Table 1. Reductions in the relative
risk of antibiotic use in treatment
studies of oseltamivir or zanamivir
as compared with placebo in
patients with inﬂuenza-like illness
Reference Study type Drug
Reduction in relative risk
of antibiotic use with active
treatment vs. placebo (%)
MIST Study Group [66] Randomised, controlled trial Zanamivir 13.0
Monto et al. [61] Pooled analysis Zanamivir 26.0
Kaiser et al. [12] Pooled analysis Oseltamivir 26.7
Nordstrom et al. [67] Retrospective cohort study Oseltamivir 11.0
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outcome in 1426 adults and adolescents; the
largest reductions in illness duration and symp-
tom severity were seen in those with the earliest
treatment initiation (Fig. 1). The same relationship
was also demonstrated in a study of over 3000
Japanese adults and adolescents [70].
Although the possibility exists of triggering the
development of resistant viral strains with anti-
viral treatments, the risk is much lower than that
for the generation of resistance in bacteria follow-
ing the use of antibiotics and is easily outweighed
by the treatment beneﬁts. Furthermore, the high
speciﬁcity of NIs for inﬂuenza viruses means that
these agents cannot exert selection pressure on
any other viruses. Administration of sub-potent
doses of an antiviral agent in the presence of the
target pathogen may trigger resistance, as is the
case for antibiotics; however, the resulting mutant
virus usually has reduced ﬁtness (e.g., reduced
infectivity, reduced transmissibility) [71–74].
PATHS TO IMPROVEMENT
There are two ways of responding to the chal-
lenge posed by inﬂuenza infections and the
misuse of antibiotics: ﬁrst, by using NIs to either
minimise the severity and length of the inﬂuenza
illness or to prevent inﬂuenza in the ﬁrst place;
and second, by the use of clinical and diagnostic
tests to identify a patient who has inﬂuenza and
does not require an antibiotic. Experience in
Finland and Iceland has already shown that
bacterial resistance rates decrease following a
reduction in antibiotic use on a national scale. In
Finland, the use of macrolides decreased by 42%
between 1991 and 1992, and then remained steady
for the next 4 years; during 1991–1996, the inci-
dence of erythromycin resistance in GAS isolated
from throat swabs decreased by c. 50% [75].
Preliminary data have indicated that a similar
programme in Iceland resulted in a decrease in
the incidence of penicillin-resistant pneumococci,
from 20% in 1993 to 16.9% in 1994 (K. Kristensson,
M. A. Hjamasdottir and T. H. Gudnason, unpub-
lished results).
The number of antibiotic courses prescribed
appropriately for cases of URTI, bronchitis, otitis
media and other infections could also be limited
by preventing the infections themselves. It is
evident that shortening the duration and severity
of inﬂuenza illness in more patients through
wider adoption of effective antiviral therapy with
NIs should also cause the incidence of secondary
bacterial infection to decrease, thereby directly
reducing the number of antibiotic courses pre-
scribed to these patients. This dual approach
could potentially reduce the risk of antibacterial
resistance while more effectively treating inﬂu-
enza and its complications.
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